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© 2011 Japanese Society of Tropical Medicine Abstract: Huge emphasis has been placed on the role of the adaptive immune system in dengue pathogenesis.
Yet there is increasing evidence for the importance of the innate immune system in regulating dengue infection
and possibly influencing the disease. This review focuses on the interplay between the innate immune system and
dengue and highlights the role of soluble immunological mediators. Type I and type II interferons of the innate
immune system demonstrate non-overlapping roles in dengue infection. Furthermore, while some IFN responses
to dengue are protective, others may exert disease-related effects on the host. But aside from interferons, a number
of cytokines have also been implicated in dengue pathogenesis. Our expanding knowledge of cytokines indicates
that these soluble mediators act upon a complicated network of events to provoke the disease. This cytokine storm
is generally attributed to massive T cell activation as an outcome of secondary infection. However, there is reason
to believe that innate immune response-derived cytokines also have contributory effects, especially in the context of
severe cases of primary dengue infection. Another less popular but interesting perspective on dengue pathogenesis
is the effect of mosquito feeding on host immune responses and viral infection. Various studies have shown that
soluble factors from vector saliva have the capacity to alter immune reactions and thereby influence pathogen
transmission and establishment. Hence, modulation of the innate immune system at various levels of infection is
a critical component of dengue disease. In the absence of an approved drug or vaccine for dengue, soluble mediators
of the innate immune system could be a strategic foothold for developing anti-viral therapeutics and improving
clinical management.
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1. INTRODUCTION
Dengue virus (DV) is transmitted to a human through
the bite of an infected mosquito, particularly of the Aedes
group. The period of incubation ranges from three to seven
days [1]. Then viremia lasts for about one to seven days and
can reach 10
7 to 10
9 mosquito infectious doses (MID50)/ml
[2], which is more than sufficient to transmit the virus to
another feeding mosquito.
After its injection into the skin, DV is presumed to
undergo an initial round of replication in Langerhans
dendritic cells (LDCs) [3, 4]. Infected LDCs migrate to
draining lymph nodes [5], where infection spreads to
monocytes and macrophages [6]. The lymphatic system
may then play a key role in the ensuing viremia, through
which the virus can be disseminated to other organs such as
the spleen, liver and bone marrow [6].
The clinical manifestation of dengue ranges from mild
febrile syndrome to fatal disease [1]. Dengue fever (DF) is
an acute and self-limited illness manifested by fever,
headache, myalgia and arthralgia, with physical evidence of
rash. Laboratory tests reveal leukopenia, as well as varying
degrees of thrombocytopenia and hemorrhage. The more
severe dengue hemorrhagic fever (DHF) is complicated by
Department of Virology, Institute of Tropical Medicine, GCOE Programme, Nagasaki University, 
Sakamoto machi 1-12-4, Nagasaki 852-8523, Japan
*Corresponding author: 
Tel: +81-95-819-7829    
Fax: +81-95-819-7830    
E-mail: moritak@net.nagasaki-u.ac.jp54 Tropical Medicine and Health Vol.39 No.4 Supplement, 2011
plasma leakage that occurs around three to five days after
the disease. A sudden and extensive plasma leakage may
result in shock or death, a phenomenon called dengue shock
syndrome (DSS). Typically, patients undergo a deferves-
cence phase marked by an abrupt drop in body temperature,
at which point the illness may either wane to recovery or
proceed to serious complications [7].
Dengue is widely accepted to be an immunopathological
disease. Compounding evidence also associates dengue
severity with secondary infection of a heterologous serotype
[8–11]. From this perspective, dengue pathogenesis can be
explained through various hypotheses that implicate immune-
related factors, including the: 1) enhancement of viral
infection through cross-reactive antibodies, 2) activation of
cross-reactive memory T cells, 3) cytokine storm, and 4)
complement activation. Unfortunately, a huge part of dengue
pathogenesis remains elusive despite years of arduous study.
In particular, while the adaptive immune response has been
central to dengue research, the initial immune events that
lead to disease evolution also warrant consideration. Thus,
we present a review of recent developments in the field of
dengue and the innate immune system, with a focus on
soluble mediators that might be involved in infection and
pathogenesis.
2. THE INNATE IMMUNE RESPONSE TO DENGUE: 
TO DEFEND OR TO DESTROY
At the onset of skin infection, DV is immediately
confronted with the host innate immune system. Whether
infection becomes limited or progresses to disease depends
on the balance between the defensive and destructive effect
of the immune response. Here we explore various soluble
mediators of the innate immune system and their role in
dengue infection. Elucidating such early events will be
valuable in shedding light on dengue pathogenesis and may
impart prognostic utility for predicting disease.
2-1. Interferons
The initial immune response to viral infection is
mediated by interferons (IFN). Most cells produce type I
IFNs (IFNα/β) to inhibit viral translation and replication.
On the other hand, type II IFNs (IFNγ) derived from NK
cells and activated T cells modulate the production of
proinflammatory and antiviral molecules. An early innate
immune response accompanied by strong upregulation of
IFN-related genes has been described for dengue [12–14].
Among the various pattern-recognition receptor (PRR)
pathways utilized by the host for IFN activation, the IPS-1/
Cardif system operated by retinoic acid-inducible gene I-
like helicases (RLH) appears to be the most critical in
initiating the innate immune response to dengue, as exhibited
by delayed IFN production in lymphoid tissues of IPS-1-
deficient mice, rendering them more susceptible to the virus
[15]. RLH-dependent IFN activation also seems to be
regulated by the intracellular localization of flavivirus
double-stranded RNA (dsRNA). A recent study in our
laboratory demonstrated dynamic changes in Japanese
encephalitis virus dsRNA localization, which was initially
concealed in intracellular membrane structures but eventually
exposed to the cytosol [16]. This cytosolic exposure sets the
stage for PRR recognition and IFN activation, and its timing
occurs in a cell/species-specific manner, which ultimately
determines cell permissiveness to infection [16]. We are
currently exploring the applicability of this model to DV.
Other PRRs such as toll-like receptors (TLRs) may also be
involved, as TLR7 was demonstrated to be essential for
DV-induced production of IFN in plasmacytoid dendritic
cells [17].
Experiments using knock-out mice were conducted to
examine the contribution of IFN to viral clearance and
disease. Mice deficient in receptors for type I and type II
IFN were extremely vulnerable to dengue infection, while B
or T cell-deficient mice displayed a normal ability to resist
infection, demonstrating the predominant role of IFN over
the adaptive immune system in controlling primary infection
by DV [18]. Although the protective effect of type I and
type II IFNs is synergistic, their respective roles are non-
overlapping. For instance, viral distribution was widespread
in IFNα/β receptor-knockout mice, in contrast to a benign
viral titer in IFNγ receptor-knockout mice, suggesting that
type I IFNs are specifically responsible for limiting the
initial replication and/or spread of dengue [18]. However,
IFNγ receptor-knockout mice exhibited a lower survival rate
than IFNα/β receptor-knockout mice, indicating the protec-
tive role of IFNγ, but not IFNα/β, against the disease [18].
Nevertheless, type I IFNs and other IFN-stimulated
genes have been associated with disease severity in several
clinical studies. These studies are characterized by the
consistent theme of highly activated type I IFN response in
uncomplicated cases of dengue, in contrast to a blunted IFN
profile in severe cases [19–21]. Clearly, IFN serves as an
early barrier against infection in mild cases of dengue, but is
overridden or no longer functional in severe forms of the
disease. A dampened IFN response could additionally cause
the enhanced viremia associated with severe dengue [2].
This differential immune response can be accounted for by
an altered profile of IFN-producing innate immune cells
during disease progression. For example, expansion of
TLR-expressing monocytes was observed in mild, but not
severe forms of dengue [22], and plasmacytoid dendritic
cells decreased at an accelerated rate in DHF compared55 L.A. Espada-Murao et al.
to DF patients [23]. It is not clear how these immune cells
are differentially modulated, but it would certainly be an
interesting aspect of dengue research. Suppressed IFN
expression in severe dengue can also be explained by the
antibody-dependent enhancement theory. According to Ubol
et al. [24], DV-antibody complexes trigger negative regula-
tors that disable IFN production in monocytes. Consistent
with this finding is the observation that IFNβ, RLH and
IPS-1 levels were downregulated in peripheral blood
mononuclear cells of secondary DHF patients but not in
secondary DF patients [24]. But since both groups have
pre-existing antibodies to DV, other components such as
antibody type may factor in on the repressed type I IFN
profile of severe secondary dengue infections. For example,
the overall effect on IFN response may vary from patient
to patient, depending on the combination of enhancing and
neutralizing antibodies present in the host.
For the type II IFN response, the correlation between
IFNγ levels and disease severity is not so clear. Bozza et al.
[7] observed higher IFNγ levels in severe versus mild
dengue, and suggested its predictive utility for disease
severity. Kadhiravan et al. [25] and Restrepo et al. [26]
also observed higher IFNγ levels in DHF/DSS patients.
However, in another study, IFNγ was higher in primary
versus secondary infections but did not correlate with
severity [27]. This inconsistency may be due to differences
in study design, population sampling, and timing of cytokine
measurements, which is difficult to standardize. Thus,
sequential measurement of cytokine levels is a better option
for a thorough analysis of IFN levels. Using this approach,
Libraty et al. [28] and Priyadarshini et al. [29] observed
earlier peak plasma IFNγ among DHF patients compared to
DF patients. Furthermore, a significant number of DHF
cases with plasma leakage had increased levels of IFNγ,
indicating its role in dengue pathogenesis [29]. Possible
sources of IFNγ are NK cells and T cells, which are highly
activated in DHF versus DF patients [30, 31]. IFNγ modu-
lates the microenvironment of immune cells by enhancing
the activation of DV-infected dendritic cells (DC) and the
release of IL-12, a T-cell activating cytokine [32]. IFNγ
has also been shown to augment antibody-mediated dengue
infection of monocytic cells and DCs [32–34]. Furthermore,
IFNγ directly affects endothelial cell permeability [35, 36].
A combination of these effects is a fine recipe for a dysfunc-
tional immune system. Hence, although IFNγ is originally
designed to protect against disease [18], it may potentially
inflict damage on the host, depending on the timing and
level of production, and in concert with other pathogenic
events of dengue infection.
A novel insight into the relationship between IFN and
plasma leakage has been explored in an in vitro study on
endothelial cells [37]. DV infection imparted a protective
effect against TNFα-mediated hyperpermeability of endo-
thelial cells at early periods of infection, but this protective
effect diminished after several days of infection. The authors
further proved that IFNβ mediates this protective activity
against vascular permeability. But as IFNβ production
wanes at later phases of infection, endothelial cells become
more sensitized to TNFα-induced permeability. Indeed, the
addition of recombinant IFNβ during late-stage infection
restored the endothelial cells to normal permeability [37].
Type I IFNs have been shown to stabilize the vascular
barrier in various studies [38–41]. Moreover, IFNα and
IFNβ protect against IFNγ-induced endothelial permeability
[42]. Based on these findings, it is tempting to speculate on
a model for IFN-mediated pathogenesis of dengue. IFNγ, as
well as other unknown factors, may be responsible for
plasma leakage in dengue patients. However, a strong type I
IFN response in mild dengue protects against vascular
permeability, aside from controlling viral replication. On
the other hand, a muted type I IFN response in severe dengue
is unable to block either infection or plasma leakage. While
this hypothesis sounds promising, it is challenged by the
lack of an appropriate animal model for dengue disease [43].
2-2. Cytokines
The cytokine storm theory proposed for dengue claims
that a dysregulated production of cytokines during DV infec-
tion contributes to the disease. These cytokines are believed
to be a product of massive T cell activation [44, 45].
According to the “original antigenic sin” proposed by
Mongkolsapaya  et al. [46], preferential expansion of
memory T cells from primary infection over high-affinity T
cells for the current infection promotes cytokine responses
that imperil rather than protect the host. However, this does
not explain DHF/DSS in infants with primary infection.
Upregulated levels of cytokines have also been reported
for dengue patients at the age of less than 1 year [47–49],
indicating that altered cytokine profiles are not solely
directed by the cell-mediated immune response. It can be
hypothesized that instead of T cells, maternal antibody-
enhanced viremia is responsible for the increased cytokine
response in infant cases of dengue [47, 48], most likely
from cells of the innate immune system which are targets
for initial replication of DV. For example, in vitro experi-
ments show that monocytes and DCs could act as important
sources of cytokines during DV infection [50–52].
Accordingly, Chen et al. [51] proposed a model for dengue
pathogenesis in which cytokine production by monocytes
during early DV infection triggers a cascade of events that
eventually leads to an augmented cytokine response, thereby
causing vascular permeability.56 Tropical Medicine and Health Vol.39 No.4 Supplement, 2011
The current challenge of dengue research is to identify
soluble factors that mediate pathogenesis, and a number of
candidate cytokines have been identified. The reader is
referred to other articles for a more comprehensive over-
view regarding these molecules [53–55]. Despite these
leads, the definite cytokine determinant of dengue severity
is still not established. Thus, an alternative approach is to
identify the central regulator of cytokine expression during
DV infection. So far, two such putative regulators have been
identified. DV infection of macrophage inhibitory factor
(MIF)-deficient mice produced a less severe clinical
disease, with reduced proinflammatory cytokine levels [56].
Moreover, anti-MIF antibodies reduced cytokine expression
in DV-infected macrophages [56]. These results suggest
the involvement of MIF in the amplification of cytokine
responses that inflict damage on the host. Elevated levels of
MIF have been detected in severe dengue [56, 57], and
macrophages and hepatocytes were identified as sources of
this cytokine [56]. CLEC5A is another molecule implicated
in dengue pathogenesis. CLEC5A is a C-type lectin
expressed exclusively on monocytes and macrophages.
Knockdown of CLEC5A suppressed monocyte production
of proinflammatory cytokines without any effect on viral
entry [58]. Furthermore, treatment of anti-CLEC5A anti-
bodies in DV-infected STAT-deficient mice abrogated pro-
inflammatory cytokine expression without affecting viral
replication, prevented hemorrhage and vascular perme-
ability, and reduced mortality [58]. Hence, CLEC5A may
also act as a central regulator of pro-inflammatory cytokine
responses during DV infection. However, this hypothesis
contrasts with a recent study, which reports that CLEC5A
expression is downregulated in dengue patients [59].
Hence, more extensive clinical data is required to confirm
the importance of CLEC5A in dengue pathogenesis.
Another aspect of the cytokine storm theory that
requires evaluation is how the cytokine storm develops and
causes disease. One relevant hypothesis is that cytokines
may not necessarily behave in a linear fashion but rather
as a complex network of events. Chen et al. [51] proposed
that cytokine production during DV infection occurs in a
hierarchichal manner, progressing from a local gradient
derived from monocytic cells and expanding further as other
immune cells are recruited and activated. This complex
nature of cytokines makes it difficult, if not impossible, to
pinpoint the exact mediator of dengue severity.
To complicate things further, cytokines may not act
alone but instead exert a synergistic effect in unison. For
example, IL-4 exerts a synergistic effect on endothelial cell
permeability when combined with either TNFα or IFNγ
[60], and increased expression of all three cytokines has
been reported in severe dengue [7, 25, 26, 52, 61, 62].
Hence, aside from increased cytokine levels, the cytokine
profile of dengue patients should also be investigated.
When patients with severe dengue were compared, the
primary infection group (infants less than 1 year of age) and
the secondary infection group (older children) similarly
had elevated levels of IFNγ and IL-10, but IL-6 and TNFα
were additionally upregulated in infants [48]. A specific
combination of cytokines, instead of a solo cytokine, may
be a prerequisite for disease development.
The timing of cytokine production also plays a role in
the evolution of disease. To illustrate, IL-6 and IL-8 levels
increased earlier in DHF compared to DF cases [29]. IL-6
levels were associated with the presence of pleural effusion/
ascites in DHF, while IL-8 correlated with thrombocytopenia
and increased serum alanine transaminase levels, an indicator
of hepatic injury [29]. IL-8 has also been shown to mediate
vascular permeability during DV infection [63]. The early
appearance of these cytokines in DHF could enhance or
hasten immunopathological events that lead to disease
progression.
Finally, viral load also has an influence on the induc-
tion potential of cytokines. The minimum viral inoculation
level required for cytokine expression in monocytes varies
to a significant degree. While IL-8, MIP-1α and RANTES
could be induced by a small viral input, TNFα and IL-1β
demanded high doses of DV [51]. Thus, certain cytokines
are readily inducible during the initial phases of DV infec-
tion, while others remain unexpressed or unaltered until
high-titer viremia or tissue viral load is established. This
probably explains the hierarchical expression of cytokines
during DV infection, and thereby justifies the comprehensive
analysis of cytokine profiles at different periods of illness to
improve our understanding of dengue pathogenesis.
3. MOSQUITO-DERIVED IMMUNOMODULATORS 
IN FLAVIVIRUS INFECTION
When the host is bitten by a pathogen-transmitting
arthropod, it also encounters saliva-associated factors.
Arthropod saliva has been shown to manipulate host
hemostasis in order to facilitate blood feeding. Almost all
blood-feeding arthropods studied so far have at least one
anti-clotting, one vasodilator, and one anti-platelet compound
[64]. But research also shows that the saliva of ticks,
blackflies, sand flies and mosquitoes have the capacity to
regulate the host immune system [64–69], indicating that
immunomodulation may be common among hematophagous
arthropods. For arthropods that live in long-term, close
association with their host (e.g. ticks), immune regulation
serves the obvious purpose of averting host reactions that
impede feeding and survival. But for rapid feeders like57 L.A. Espada-Murao et al.
mosquitoes, the arthropod has already terminated contact
with the host by the time the immune defense reaches its
climax. Thus, Schneider and Higgs [70] proposed two
hypotheses to explain the immunomodulatory activity of
mosquito saliva. Since the host is frequently exposed to
mosquitoes, immune reactions to a previous exposure must
be modeled to allow subsequent feeding. Alternatively,
these inflammation and immune responses are by-products
of mosquito anti-hemostatic activities, since these three
physiological pathways are closely intertwined. In the
context of arthropod-borne infections, vector saliva may
alter immune reactions in a way that can influence pathogen
transmission and establishment, as has been demonstrated
for Leishmania major, Plasmodium yoleii, Cache Valley virus
and vesicular stomatitis virus [71–74]. Thus, mosquito saliva
has the potential to direct the course of flavivirus infections,
specifically by interrupting the innate immune response.
This section evaluates the impact of soluble mediators from
mosquito saliva on the earliest process of dengue infection,
as the virus initially establishes itself in the host.
Although research has been done on various mosquitoes,
this review focuses on Aedes aegypti, the most important
vector for dengue, with reference to other vectors. Mosquito
feeding or saliva from A. aegypti creates a shift from Th1
cytokine to Th2 cytokine expression. Th1 cytokines such as
IFNγ and IL-2 were downregulated [68, 75–78], while Th2
cytokines such as IL-4, IL-5 and IL-10 were either upregu-
lated or unaffected [68, 75, 76, 78, 79], although in one
case IL-10 was downregulated [77]. This is attributable to
differences in preparation and/or dose of salivary gland
extract (SGE) and the mice used. Culex pipiens feeding
also favored Th2 cytokine responses [78]. A Th1-to-Th2
shift in cytokine response has been observed in severe
dengue [25, 80], but there is no direct evidence so far
linking this to mosquito bites. Th1 cytokines stimulate a
proinflammatory response to kill intracellular parasites. On
the other hand, Th2 cytokines have a counteractive effect on
Th1 cytokines, and their function is targeted toward extra-
cellular pathogens. Hence, a Th2-skewed cytokine response
during mosquito feeding would benefit viral transmission
and initial establishment in the host. In support of this,
reconstitution of Th1 cytokines during vector feeding
restored innate immunity and restricted infection by Borrelia
burgdorferi, an intracellular spirochete, in mice [81].
Furthermore, other antiviral mediators such as IFNβ, iNOS
and TLR3 were suppressed by mosquito feeding/saliva
[75, 76, 79].
T cells are also largely affected by mosquito saliva. For
example, A. aegypti SGE restricted splenocyte proliferation
by inducing cell death and arresting cell division, with T
lymphocytes as the most susceptible population [68, 77].
Dermal recruitment of T cells was also inhibited when mice
were subjected to mosquito feeding prior to WNV infection
[79]. Thus, mosquito bite-mediated T cell suppression can
be exploited by DV for transmission and survival. In
contrast, SGE from Culex quinquefasciatus did not affect T
cell proliferation [77], although its effect on other immune
cells was not investigated. This differential activity is
probably due to biological differences between the two
vectors, which may eventually influence host preference of
the transmitted pathogen. For example, Aedes-transmitted
viruses primarily cycle between mosquitoes and primates,
and cause hemorrhagic disease. On the other hand, Culex-
transmitted viruses usually cycle between mosquitoes and
birds, and cause neurological disease in humans, who serve
as dead-end hosts. Therefore, further studies are needed to
look into the role of mosquito-dependent immunomodulation
on host tropism and pathogenesis of arbovirus infections.
An increasing number of molecules responsible for
blood feeding have already been identified in mosquito
saliva, but the immunomodulatory components have yet to
be determined. In the case of Anopheles stephensi, Owhashi
and his group [82, 83] were able to isolate a neutrophil
chemotactic factor and an eosinophil chemotactic factor.
Zeidner  et al. [78] attributed the cytokine-modulating
activity of A. aegypti and C. pipiens saliva to sialokinins.
Sialokinins are vasodilatory molecules released into the
saliva. However, these molecules were also able to inhibit
the production of IL-2 and IFNγ while enhancing IL-10 and
IL-4 expression [78]. Thus, aside from promoting blood
feeding, sialokinins may have a secondary function in
immune modulation. Another mosquito salivary protein with
immunomodulatory property was recently isolated from A.
aegypti and identified as SAAG-4. SAAG-4 reduced IFNγ
but enhanced IL-4 response in CD4+ T cells [84]. Interest-
ingly, both sialokinin and SAAG-4 direct a Th2-skewed
pattern of cytokine response. Hence, certain substances
from mosquito saliva have the capacity for host immuno-
regulation.
Such immunological activity in mosquito saliva compels
us to contemplate on its implications for pathogen infection
and disease development. Scientific investigations along
this line have been initiated for various arthropod-borne
pathogens, including flaviviruses. Unfortunately, the majority
of flavivirus work is conducted on West Nile Virus (WNV).
Nevertheless, these findings should lay a foundation for our
knowledge regarding mosquito-flavivirus-host interactions.
Mosquito feeding/saliva-mediated enhancement of WNV
infection has been demonstrated in mice using Aedes
aegypti and Culex tarsalis [79, 85, 86], and in chicken using
C. pipiens [87]. In the mouse studies, mosquito feeding
increased viremia and accelerated neuroinvasion compared58 Tropical Medicine and Health Vol.39 No.4 Supplement, 2011
to needle injection. When mosquito feeding was artificially
mimicked in mice using SGE treatment prior to needle
infection, the enhanced infection was similarly achieved
[85, 86]. But when SGE was applied at a site distal from
the infection, the enhancing effect was lost [86]. These
results indicate that mosquito saliva is responsible for the
augmented infection and that this activity is mediated
locally. However, the effect of mosquito saliva on mortality
is not clear. Schneider et al. [85] described a lower survival
rate among mosquito fed-WNV infected mice, but Styer
et al. [86] did not observe any differences in morbidity,
mortality, onset of disease or survival time. This discrepancy
may be due to differences in the mosquitoes or mice used
or to the experimental methods employed. But it is also
possible that mosquito feeding may enhance viral replica-
tion without affecting the outcome of disease. Further studies
should clarify the role of mosquito-virus-host interactions
on immunopathogenesis of flaviviral infections.
Other findings do not support this mosquito saliva-
mediated enhancement theory of flavivirus infection.
Mosquito feeding did not alter WNV infection in hamsters
[88], nor did it affect the viremia and antibody response of
St. Louis encephailitis virus-infected chicken and house
finches [89]. These findings can be easily explained by
differences in experimental methodology. Alternatively,
saliva-mediated enhancement may be determined by the
combination of mosquito, virus and host species. Hence,
saliva-mediated enhancement may be or not be a universal
feature of flavivirus infections. In the case of DV, only one
study on mosquito saliva has been conducted. A. aegypti
saliva inhibited DV infection of human myeloid DCs, and
this effect was augmented when cells were pre-sensitized
with saliva, leading the authors to conclude that mosquito
saliva has instead an antiviral function [90]. At this point, it
is difficult to generalize since the effect of mosquito saliva
on DV infection in other susceptible cells or in vivo has
not yet been investigated. To resolve this, more extensive
research on mosquito saliva and its role in DV infection
and pathogenesis is recommended. Nevertheless, mosquito
saliva has immunomodulatory effects that can be exploited
by DV to enhance transmission and infection. Although there
is no compelling evidence for this as yet, the findings based
on WNV emphasize the impact of vector feeding on early
events of flavivirus infection.
4. PROSPECTS FOR DENGUE MANAGEMENT 
AND THERAPY
The identification of soluble factors required for
dengue infection and pathogenesis would facilitate the
development of anti-viral and disease management strategies.
Until now, no therapeutic drug has been developed for
dengue, and the success of hospital treatment relies heavily
on careful observation and supportive care. With up to 50
million DV infections every year [91], the race is on to find
an improved intervention method for dengue.
The success of IFN in hepatitis B and C virus therapy
prompted some researchers to look into its utility for dengue.
IFNα has been shown to inhibit DV replication in vitro
using various cell lines [92–94]. To assess its effectiveness
in vivo, two types of rIFN-α-2a (nonpegylated and pegylated)
were administered in DV-infected rhesus monkeys one day
after the onset of viremia [92]. The pegylated form has a
covalently conjugated 40kD branched methoxy-polyethylene
glycol (PEG) molecule, which prolongs the systemic pre-
valence of rIFN-α-2a. A single administration of either
preparations inhibited DV replication to some extent, but
not completely [92]. The nonpegylated form delayed viremia,
while the pegylated form slightly reduced viral titers. In
future studies, a combination of the two forms is recom-
mended to potentiate absolute clearance of the virus. rIFN-
α-2a surpasses other antiviral drugs for its clinical safety
and tolerability, especially among children [95]. Furthermore,
if a single dose administration is proven to be effective, IFN
treatment would be simple and affordable. A combination
therapy with other antiviral drugs may also increase its
potency. However, since dengue viremia peaks within the
first 72 hours of illness [2, 32], early intervention is an
important prerequisite for the success of this strategy.
Another therapeutic approach is to neutralize cytokines/
cytokine mediators that promote disease. For example, anti-
body treatment against MIF and CLEC5a has been suggested
as a method of intervention. Using this strategy in mice,
cytokine production was reduced, and the clinical outcome
of DV infection was improved, suggesting its potential for
application in human dengue patients [56, 58]. Other soluble
factors are also being considered for similar purposes, but
the complex nature of cytokines precludes the identification
of a single target that can generate promising results.
Moreover, the intricate networks that link cytokines raise
the possibility of undesirable physiological effects on the
human body. Finally, whether the host is still capable of
viral clearance when certain cytokines are neutralized is a
risk that should be given proper consideration. Alternatively,
identification of soluble factors that mediate dengue severity
could be applied as clinical and laboratory tools for pre-
dicting disease, which is integral to dengue management
strategies, especially in endemic areas.
5. CONCLUSION
Dengue pathogenesis is a multifaceted phenomenon,59 L.A. Espada-Murao et al.
initially dictated by complex interactions between the virus,
vector and host, thereby resulting in a modulated immune
response. Although the adaptive immune response is usually
associated with dengue pathogenesis, the innate immune
system has much to contribute as well, especially in early
events of infection. The innate immune reaction to dengue
is characterized by the production of soluble factors that
shape the early events of infection to favor or counter the
virus. Soluble mediators may also influence disease evolu-
tion, most likely by operating on an intricate network of
reactions. Since the host operates on a critical balance of
immune responses, a disrupted equilibrium mounted by
such soluble mediators could facilitate in disease develop-
ment. The current challenge is to advance the conventional
simplistic approach of dengue immunopathogenesis research
towards a holistic strategy, which could better assist in the
development of rational, practical and effective methods for
dengue diagnosis and intervention.
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